Lipopeptide Ab

Pharmacia Ab

Conny Bogentoft

Anders Carlsson

Johan Heilborn

Mona Ståhle-Bäckdahl

Janet Tomlin

Mona St Hle-Bäckdahl

Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Use of the cathelicidin LL-37 and derivatives thereof for wound healing

Use of the cathelicidin LL-37 and derivatives therof for wound healing

Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Gel-forming liquid carrier composition

Gel-forming liquid dietary fibre composition

Growing community of inventors

Hässelby, Sweden

Conny Bogentoft